Because GBM patients with an activated PI3K/Akt/mTOR pathway have a poor prognosis (Chakravarti et al., 2004), there is a clear need for new inhibitors of this pathway as well as other pertinent targets relevant to GBM growth and survival. The gene discussed is MTOR; the disease is glioblastoma.